Cytokinetics scored the first-ever win for a Phase 3 study in non-obstructive hypertrophic cardiomyopathy on Friday. The post Cytokinetics Scores A First-Ever In Its Rivalry Against Bristol Myers appeared first on Investor's Business Daily.

How each outlet headlined it

• Investor's Business Daily right

  Cytokinetics scored the first-ever win for a Phase 3 study in non-obstructive hypertrophic cardiomyopathy on Friday. The post Cytokinetics Scores A First-Ever In Its Rivalry Against Bristol Myers appeared first on Investor's Business Daily.
• STAT News

  It took Cytokinetics 27 years to win its first drug approval. With the results of a new trial, its second could come much faster.